| Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
Akero Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 7, 2024. The Company’s stockholders approved an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law. The certificate of amendment of the Company’s Fourth Amended and Restated Certificate of Incorporation (the” Certificate of Amendment”), was filed with the Secretary of State of the State of Delaware on June 11, 2024 and became effective upon filing.
The foregoing description is qualified in its entirety by the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
As of April 10, 2024, the record date for the Annual Meeting, there were 69,151,007 outstanding shares of the Company’s common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission (“SEC”) on April 26, 2024: (i) to elect three directors, Seth L. Harrison, M.D., Graham Walmsley, M.D., Ph.D., and Yuan Xu, Ph.D., as Class II directors of the Company to each serve for a three-year term expiring at the Company’s annual meeting of stockholders in 2027 and until their respective successors have been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”), (ii) to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Proposal 2”), (iii) to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers (“Proposal 3”) and (iv) to approve an amendment to our Fourth Amended and Restated Certificate of Incorporation to limit the liability of certain directors of the Company, as permitted by recent amendments to Delaware law (“Proposal 4”).
The Company’s stockholders approved the Class II director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for Class II directors as follows:
| | | | | | | | | | | | |
| Class II Director Nominee | | For | | | Withheld | | | Broker Non-Votes | |
Seth L. Harrison, M.D. | | | 16,924,611 | | | | 38,742,993 | | | | 3,920,264 | |
Graham Walmsley, M.D., Ph.D. | | | 35,755,718 | | | | 19,911,886 | | | | 3,920,264 | |
Yuan Xu, Ph.D. | | | 18,067,658 | | | | 37,599,946 | | | | 3,920,264 | |
The Company’s stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2. The votes cast at the Annual Meeting were as follows:
| | | | | | |
| For | | Against | | Abstain | | Broker Non-Votes |
| 59,238,349 | | 37,608 | | 311,911 | | 0 |
The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers in Proposal 3. The votes cast at the Annual Meeting were as follows:
| | | | | | |
| For | | Against | | Abstain | | Broker Non-Votes |
| 52,835,974 | | 2,548,327 | | 283,303 | | 3,920,264 |
